Jay L. Patel
No Rating Available
(Learn About Our Rating System)

Jay L. Patel, MD, MBA

Languages spoken: English

Dr. Patel is a Professor in the Department of Pathology at the Spencer Fox Eccles School of Medicine at the University of Utah. In addition, Dr. Patel serves as Vice President of Clinical Trials & PharmaDx at ARUP Laboratories. He received his MD from the University of Arizona and completed a residency in anatomic and clinical pathology at the University of Utah. Dr. Patel then served as a hematopathology fellow at Stanford University. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology. He is keen on application of next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies and benign hematologic disorders.

Specialties

  • Hematopathology
  • Pathology, Clinical
  • Pathology, Anatomical

Board Certification

American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Hematology)

Dr. Patel is a Professor in the Department of Pathology at the Spencer Fox Eccles School of Medicine at the University of Utah. In addition, Dr. Patel serves as Vice President of Clinical Trials & PharmaDx at ARUP Laboratories. He received his MD from the University of Arizona and completed a residency in anatomic and clinical pathology at the University of Utah. Dr. Patel then served as a hematopathology fellow at Stanford University. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology. He is keen on application of next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies and benign hematologic disorders.

Board Certification and Academic Information

Academic Departments Pathology -Professor (Clinical)
Board Certification
American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Hematology)

Education history

Undergraduate Molecular & Cellular Biology - University of Arizona B.S.
Professional Medical Medicine - University of Arizona M.D.
Residency Anatomic and Clinical Pathology - University of Utah Resident
Fellowship Hematopathology - Stanford University Fellow
Graduate Training Business Management - University of Utah M.B.A.

Selected Publications

Journal Article

  1. Vannucchi AM, Patel JL, Kiladjian J (2026). Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib. Blood,
  2. Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami R (2025). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia, 39(1), 248-256.
  3. Pandiri M, Stengel A, Zhang J, Wang P, Shao H, Velmurugan S, Jacob A, Symes E, Kaur A, Rojek A, Sojitra P, Wiredja D, Zhou Q, Chang H, Patil E, Patel JL, Patel AB, Menon M, Ghosh S, Wool GD, Arber DA, Pan Z, Findley A, Badar T, Tariq H, Sallman D, Bell RC, Perry A, Haferlach C, Fitzpatrick C, Venkataraman (2025). Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. Journal of clinical pathology, 78(9), 629-635.
  4. Verstovsek S, Kiladjian JJ, Vannucchi AM, Patel JL, Rambaldi A, Shomali WE, Oh ST, Usuki K, Harrison CN, Ritchie EK, Akard LP, Hernández-Boluda JC, Huguet F, Colucci P, Zhen H, Oliveira N, Gilmartin A, Langford C, George TI, Reiter A, Gotlib (2025). Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement. NEJM evidence, 4(9), EVIDoa2500017.
  5. Kaur A, Rojek AE, Symes E, Nawas MT, Patel AA, Patel JL, Sojitra P, Aqil B, Sukhanova M, McNerney ME, Wu LP, Akmatbekov A, Segal J, Tjota MY, Gurbuxani S, Cheng JX, Yeon SY, Ravisankar HV, Fitzpatrick C, Lager A, Drazer MW, Saygin C, Wanjari P, Katsonis P, Lichtarge O, Churpek JE, Ghosh SB, Patel AB, Menon MP, Arber DA, Wang P, Venkataraman (2024). Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood cancer journal, 14(1), 99.
  6. Suknuntha K, Geyer JT, Patel KP, Weinberg OK, Rogers HJ, Lake JI, Lauridsen L, Patel JL, Kluk MJ, Arber DA, Hsi ED, Bagg A, Bueso-Ramos C, Orazi (2023). Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leukemia research, 127, 107033.
  7. Agarwal AM, McMurty V, Clayton AL, Bolia A, Reading NS, Mani C, Patel JL, Rets (2023). Clinical Utility of Targeted Next-Generation Sequencing Panel in Routine Diagnosis of Hereditary Hemolytic Anemia: A national reference laboratory experience. European journal of haematology, 110(6), 688-695.
  8. Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, Abedi M, Garcia-Manero G, Kurtin SE, Maciejewski JP, Patel JL, Revicki DA, George TI, Flick ED, Kiselev P, Louis CU, DeGutis IS, Nifenecker M, Erba HP, Steensma DP, Scott B (2023). Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplantation and cellular therapy,
  9. Shomali W, Colucci P, George TI, Kiladjian JJ, Langford C, Patel JL, Reiter A, Vannucchi AM, Gotlib (2023). Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. Leukemia,
  10. Patel JL, Erba HP, Savona MR, Grinblatt DL, Clark M, Clive TC, Smart TB, Makinde AY, DeGutis IS, Yu E, Eggington JM, George T (2023). Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and Reporting. The Journal of molecular diagnostics, 25(8), 611-618.
  11. Krah NM, Miotke L, Li P, Patel JL, Bowen AR, Pomicter AD, Patel A (2023). JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome. Journal of the National Comprehensive Cancer Network, 21(12), 1218-1223.
  12. Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. Journal of the National Comprehensive Cancer Network, 20(6), 1-4.
  13. Li P, Brown S, Williams M, White TA, Xie W, Cui W, Peker D, Lei L, Kunder CA, Wang HY, Murray SS, Vagher J, Kovacsovics T, Patel J (2022). The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood, 140, 716-755.
  14. Sande CM, Wu R, Yang G, Sussman RT, Bigdeli A, Rushton C, Chitturi A, Patel J, Szankasi P, Morrissette JJD, Lim MS, Elenitoba-Johnson KS (2022). Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms. The Journal of molecular diagnostics,
  15. Osman A, Patel J (2021). Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. Clinical chemistry, 67, 1062-1070.
  16. Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George T (2021). Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. International journal of laboratory hematology, 43(3), 426-432.
  17. Li P, White T, Xie W, Cui W, Peker D, Zeng G, Wang HY, Vagher J, Brown S, Williams M, Kovacsovics T, Patel J (2021). AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia, 36, 664-674.
  18. Schumacher JA, Holgard VD, Sial F, Pearson LN, Patel JL, Karner K (2020). Detection and Quantification of FLT3 Internal Tandem Duplication Mutations Do Not Vary Significantly Between Whole Blood and Blast-Enriched Samples. American journal of clinical pathology, 153(2), 251-257.
  19. Mansoor A, Mansoor MO, Patel JL, Zhao S, Natkunam Y, Bieker J (2020). KLF1/EKLF expression in acute leukemia is correlated with chromosomal abnormalities. Blood cells, molecules & diseases, 83, 102434.
  20. *Sireci AN, *Patel JL, Joseph L, Hiemenz MC, Rosca OC, Caughron SK, Thibault-Sennett SA, Burke TL, Aisner D (2020). *Denotes equal contribution. Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular Pathology. The Journal of molecular diagnostics, 22(8), 975-993.
  21. Corean JLE, George TI, Patel JL, Li K (2019). Bone marrow findings in metastatic melanoma, including role of BRAF immunohistochemistry. International journal of laboratory hematology, 41(4), 550-560.
  22. Cessna MH, Paulraj P, Hilton B, Sadre-Bazzaz K, Szankasi P, Cluff A, Patel JL, Hoda D, Toydemir R (2019). Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. Cancer genetics, 238, 31-36.
  23. Karner K, George TI, Patel J (2019). Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. Annals of laboratory medicine, 39(6), 509-514.
  24. Shen W, Paxton CN, Szankasi P, Longhurst M, Schumacher JA, Frizzell KA, Sorrells SM, Clayton AL, Jattani RP, Patel JL, Toydemir R, Kelley TW, Xu (2018). Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing. Journal of clinical pathology, 71(4), 372-378.
  25. Sangle NA, Schmidt RL, Patel JL, Medeiros LJ, Agarwal AM, Perkins SL, Salama M (2014). Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Modern pathology, 27(8), 1137-43.